Gradient Denervation Technologies is a brand known for its innovative ultrasound-based catheter device that treats pulmonary hypertension (PH). With €14 million in funding, Gradient aims to support the clinical development and testing of this minimally invasive device designed for use in the pulmonary arteries. This groundbreaking device utilizes therapeutic ultrasound and offers a promising alternative for PH patients.

In another development, Aerami Therapeutics has developed an inhaled formulation of imatinib called AER-901, which delivers the medication through a smart, breath-activated nebulizer. In a Phase 1 trial, it demonstrated safety, good tolerability, and minimal side effects among healthy adults. These advancements in PH treatment offer hope and improved quality of life for patients.

Through their commitment to research and innovation, brands like Gradient and Aerami Therapeutics are redefining the future of pulmonary hypertension management